BIO CEO & Investor Conference
February 14, 2012
This presentation includes forward-looking statements and predictions, including statements about potential revenue-bearing transactions, the market potential of
CBLI’s technologies and product candidates, and the potential value of pipeline products. These statements represent CBLI’s judgment as of the date of this
presentation and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking
statements. In particular, CBLI faces risks and uncertainties that it may not be able to sustain its business model, that revenues may be lower or expenses higher than
projected, that product sales may not increase, that development of product candidates in the Company’s pipeline may not succeed or that commercial
transactions may not go forward as planned.
The factors that could cause actual results to differ are discussed in more detail in CBLI’s filings with the Securities and Exchange Commission, including its latest
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These reports are available under the “Investors” tab on CBLI’s website
at www.cbiolabs.com.
Safe-Harbor
2
3
• Broad pipeline of 9 drug candidates with multiple applications • 8 proprietary oncology products • Dual application for lead candidate as radiation countermeasure
• Opportunity for accelerated commercialization through biodefense
• Open IND for oncology trials
• Strategic partnerships with Cleveland Clinic and Roswell Park Cancer Institute
• Track record of non-dilutive grants and contracts (~$100M, including $30M conditional purchase for ARS countermeasure)
• Strong IP portfolio with over 20 patent applications worldwide, including composition of matter (granted patents in USA, Europe, Asia)
Investment Highlights
3
4
CBLI Corporate Structure
4
Basic Proprietary Concepts Behind CBLI’s Drugs
organism
Apoptosis
TumorNormal tissues
radiation
Imitating tumor antiapoptoticmechanisms: inhibition of p53
(Pifithrins) and activation of NF-kB (Protectans)
• Komarov et al., 1999. Science 285, 1733 • Burdelya et al., 2008. Science 320: 226
Necrosis, senescence, mitotic catastrophe
p53
NF-kB
bone marrow
lymphoid organs
small intestine
hair follicles
Restoring apoptosis in tumor cells by simultaneous activation of p53 and
inhibition of NF-kB (Curaxins)
• Gasparian et al., 2011. ScienceTransl Med 3(95): 95ra74
Understanding tumor mechanisms leads to new innovative approaches to cancer treatment and
normal tissue protection 5
Product Pipeline - CBLI Corporate
6
Product
Research Pre-Clinical
Ph I Pivotal BLA
Protectan CBLB502
Radiation Countermeasure
Product Research Pre-
clinical Ph I Ph II Ph III
Protectan CBLB502
Direct anticancer (companion diagnostic) Supportive care in oncology
Protectan CBLB612
HSC* induction & mobilization
*HSC: hematopoietic stem cells
Product Pipeline - Incuron, LLC
Product Research Pre-
clinical Ph I Ph II Ph III
Curaxin CBLC102 (non-proprietary)
Liver cancer
Curaxin CBLC137 (proprietary)
Broad anticancer
7
Product Pipeline - Panacela Labs, Inc.
Product Research Pre-
clinical Ph I Ph II Ph III
Revercom Chemo adjuvant
Mobilan Immunotherapy
Arkil Androgen Receptor Inhibitor
Antimycon Inhibitor of Myc
Oncogene
Xenomycins Anti-bacterial & Anti-fungal
8
9
Protectan CBLB502 Radiation Countermeasure
Immunotherapy against cancer Supportive care against cancer therapy side effects
9
10
Radiation Countermeasure Opportunity
10
• Nuclear attack identified by US and global leaders as number one security threat as evidenced by Reauthorization of Pandemic All Hazards Preparedness Act
• Fukushima disaster highlights risk of nuclear industry
• Drug Profile:
• 1 intramuscular injection
• Up to 48 hrs. post exposure
• Ideal for stockpile & distribution
• There are no FDA licensed countermeasures for ARS
CBLB502 uniquely positioned as therapeutic against ARS
CBLB502 as Medical Radiation Countermeasure Origin & Mechanism of Action
• Protein of bacterial origin (flagellin) pharmacologically optimized to improve stability, decrease immunogenicity and improve production yield
• Acts through multiple mechanisms mediated by activation of pro-survival NF-kB signaling pathway via highly specific interaction with innate immunity receptor TLR5
• Selectively protects normal tissues (but not malignant tumors) from radiation induced injury
• Increases survival of stem cells and early progenitors of hematopoietic system and stimulated regeneration of different HP lineages
• Reduces radiation damage to and stimulates regeneration of crypts, villi and lamina propria of GI tract
11
12
Unique Regulatory Process - FDA’s Animal Rule
12
• Efficacy in animal models that mimic human disease, with relevant end-points
• Human safety in healthy volunteers
• Well understood mechanism of action to justify selection of objective biomarkers of efficacy
• Well understood correlation of biomarker response between animal models and human volunteers to calculate dose conversion
• Fast Track and Orphan Drug Status granted
• Robust manufacturing process with 100,000s of dose equivalents on hand
FDA pathway to approve drugs where efficacy is unethical to test in humans
Days after 6.5 Gy gamma-TBI0 10 20 30 40
% o
f su
rviv
ors
0
20
40
60
80
100
vehicle (PBS), n=8
CBLB502 @ +16h, n=12
CBLB502 @ +25h, n=10
CBLB502 @ +48h, n=12
CBLB502 Efficacy
13
• N= >900 non-human primates (“NHP”s) over ~ 30 studies
• Multiple strains of mice over ~ 180 studies
• Improved survival (~20% to ~80%)
• CBLB502 reduced damage to HP and GI systems, spleen, thymus and lymph nodes = increased survival and improved quality of life
Mitigation
CBLB502 Safety in Humans
14
• 150 healthy volunteers received 2-50 µg in 2 studies
• Adverse event profile is predictable and directly related to mechanism of action (short-lasting “flu-like” syndrome):
• Activation of TLR5 in cell types distinct from those targeted by agonists of other TLRs, that produce a uniquely safe, though powerful, spectrum of cytokines (G-CSF, IL-6, IL-8, IL-10)
• No induction of cytokine storm-generating cytokines
• Methodology established to determine projected human efficacious dose (based on biomarkers)
Projected efficacious dose in humans below DLT
CBLB502 Countermeasure Path to Licensure
15
Completed Remaining steps
CMC
GMP process developed and tested, drug suitable for clinical trials released, 100,000s
dose equivalents on hand
Additional consistency runs
Efficacy
Data from ~1,000 primates demonstrates dramatic survival benefits and accelerated
recovery
Pivotal animal studies
Human safety
Two trials: 50-subject dose-escalation and 100-subject study completed Definitive safety study
FDA process
Open IND, Fast Track Status,
Orphan Drug Status Package preparation and
BLA submission
16
Protectan CBLB502 Medical Applications
16
17
Direct Anti-tumor Effects of CBLB502 (summary)
healthy
TLR5- tumors in liver
TLR5+ tumors in liver
TLR5+ tumors
TLR5- tumors
CB
LB5
02
No toxicity
Tumor suppression
Tumor suppression
Tumor suppression
No antitumor effect
TLR5-negative tumors
TLR5-positive tumors
CBLB502 is active against TLR5+ tumors and against TLR5+/- liver metastases
Companion diagnostic
assay in development
Direct Anticancer Efficacy of CBLB502*
Time (Days)
Me
an T
um
or
We
igh
t (m
g)
0 4 8 12 16 20 24 28 32 36 40 44 48 52Me
an
Tu
mo
r W
eig
ht
(mg
)
200
500
2000
5000
100
1000
10000
Indivadual rat bearing advanced Ward colorectal carcinoma
response to CBLB502 0.2 mg/kg/day by i.p. daily x 5
Time (Days)
0 4 8 12 16 20 24 28 32 36 40 44 48 52
Me
an
Bo
dy
We
igh
t (%
)
90
95
100
105
110
115
Rat # 1
Rat # 2
Rat # 3
Rat # 4
"Toxicity"
"Antitumor Activity"
0
CBLB502, x3 daily, 0.2 mg/kg
200
500
2000
5000
1000
10000
Control (mean)
Treated (individual animals)
* * *
CBLB502 3xdaily 0.2 mg/kg
CBLB502 as a single agent can cause complete tumor regression of Wart colon tumors in Fisher rats *
18
* unpublished data
Intact
Anti-Fas
CBLB502 + anti-Fas
con
tro
l C
BLB
50
2
• CT26, TLR5-negative syngeneic colon cancer was grown as liver metastases in Balb/c mice
• Tumor growth was monitored using luminometer imager (tumors express luciferase)
CBLB502 Against Liver Metastases of Colon Cancer *
19
* unpublished data
Control (no drug) CBLB502, 5hrs post injection
immunocyte infiltration
0 10 20 30 400.0
0.5
1.0
Intact (n=5)CBLB502+anti-Fas (n=9)
days
Tum
or-
free
frac
tio
n
Tumor suppressive effect of a single injection of CBLB502 is associated with tumor infiltration with immunocytes
CBLB502 Against Radiotherapy Side Effects
20
Toll-like Receptor 5 Agonist Protects Mice from Dermatitis and Oral Mucositis Caused by Local Radiation: Implications for Head and Neck Cancer Radiotherapy 2
Hair follicle
Epidermis
euthanasia required at 25% weight loss
Cross sections at day 14
21
CBLB502 Competitive Landscape*
Radiation Mitigation Cellerant (CLT-008) - myeloid progenitor cells targeting hematopoietic system
Aeolus (AEOL 10150) - small molecule antioxidant targeting lung and GI
Neumedicines (HemaMax) - recombinant human IL-12 targeting hematopoietic system
Onconova (ExRad) - modulator of DNA repair pathways targeting overall survival
Araim (ARA290) - short peptide interacting with tissue protective receptor targeting hematopoietic system
RxBio (Rx100) - small-molecule analog of an endogenous, pro-survival molecule targeting overall survival
MedImmune (Amifostine) – cytoprotective agent targeting xerostomia in head and neck cancer
Solgenix (SGX201) – corticosteroid targeting acute radiation enteritis
CBLB502 only known agonist of TLR5, triggering both pro-survival mechanisms & innate immune response
* Sampling compiled from public data
22
Protectan CBLB612 Mobilizer of Hematopoietic Stem Cells
22
23
CBLB612 Overview
• Synthetic proprietary derivative of Mycoplasma lipopeptide 5
• TLR2/6 agonist
• Powerful inducer and mobilizer of hematopoietic stem cells (HSCs)
• Works synergistically with G-CSF (Neupogen®) and AMD3100 (Mozobil®)
• Potential clinical applications: • mitigation of neutropenia (compromised immune system) • stem cell transplantation without aphaeresis
Synergistic effect of CBLB612, G-CSF, and AMD3100 on HSC mobilization*
24
To
tal C
FC
nu
mb
er
pe
r 1
ml o
f P
B, x 1
00
0
* unpublished data
Principle efficacy assessment in Phase I = potential partnering
CBLB612 Product Development Strategy
25
A Phase I safety study in healthy volunteers should enable accurate estimates of induction
and mobilization of stem cells in peripheral blood, a direct predictor of efficacy of the drug
26
Curaxins Small Molecule Anticancer Therapeutics
26
27
27
Curaxins
• Synthetic small molecules with proprietary structure
• Unique molecular target (FACT): simultaneous modulation of four signal transduction pathways commonly deregulated in cancer:
• Suppression of NF-kB • Activation of p53 • Suppression of Heat Shock Factor 1 • Suppression of Hypoxia Inducible Factor a
• Efficacious in a broad spectrum of preclinical tumor models
• In vivo anti-cancer efficacy demonstrated for IV and oral routes
• Lack of genotoxicity suggests safe applications including cancer prophylaxis
• $5 million prestigious Russian government Skolkovo grant awarded September 2011
28
28
Recent Peer Review of Curaxins
• Science Translational Medicine (2011)6
“These results introduce FACT as a novel target for anticancer therapy. The
broad anti-tumor activity of curaxins, their previously unidentified mechanism
of action – which apparently does not rely on the induction of DNA damage –
and their ability to affect multiple pathways fully justify a continued effort in
evaluating them as anticancer agents that could possibly hit the clinic.”
- excerpt from accompanying Perspective by Giulio Draetta (Dana
Farber Cancer Institute) and Ronald DePinho (President, Univ. of Texas
MD Anderson Cancer Center)
• Journal of Virology (2010)7
• Cell Cycle (2009)8
• Oncogene (2009)9
Anti-tumor effect of CBLC137 in multiple human cancer xenografts in mice 6
Caki-1: renal cell carcinoma DLD-1: colon carcinoma Mel-7: melanoma PDA: pancreatic ductal adenocarcinoma * - indicates statistical significance
29
Synergy of CBLC137 and known anticancer therapeutic: Activity against aggressive tumor in mice*
30
CBLC137 alone
known anticancer drug alone
CBLC137 + known anticancer drug
* unpublished data
Pe
rce
nt
surv
ival
Time to Medium palpable tumor
Vehicle
31
31
Incuron, LLC – JV for Curaxin Development
• Joint venture with BioProcess Capital Partners LLP, Moscow
• ~$15M to reach inflection points for primary molecules
• CBLI oversees mechanistic studies and formal development
• Ongoing dosing of Phase Ib trial for prototype CBLC102 in gastrointestinal and liver cancer patients in Russia
• Phase I trial with oral formulation of next generation CBLC137 in solid tumors planned for 2012 in Russia
• Optimization of IV formulation of next generation CBLC137 for future trial in US underway
32
Anticancer Therapeutics & Anti-Infectives
32
33
33
Panacela Labs, Inc.
• Joint venture with Open Joint Stock Company “RUSNANO”, $10B Russian Federation fund
• IP Partners: Roswell Park Cancer Institute, Cleveland Clinic, Children’s Cancer Institute Australia
• Commitment from RUSNANO: $9M received, 17M over four years, based on milestones
• Portfolio of five compounds entering formal pre-clinical development or hit-to-lead optimization
• Strategy – to accelerate human data and licensure in Russian market
34
34
CBLI Milestones CBLB502 Defense (all in discussion) • BARDA development contract • Start of pivotal animal efficacy studies • Start of definitive safety/dose validation trial in healthy volunteers
CBLB502 Medical • Trial as single agent in advanced cancer patients (enrollment open) • Trial as supportive care in head and neck cancer patients (protocol in
development)
CBLB612 • Complete formal pre-clinical development (in process)
Incuron • Complete dosing of CBLC102 trial in Russia (enrolling) • Phase I trial of CBLC137 in Russia (IND filed) • IV formulation and pre-clinical development of CBLC137 in US (in process)
General • High profile peer reviewed publications (some submitted, others in process)
35
35
Financial Summary
• Shares Outstanding: 35M common, 52M fully diluted
• Government Grants & Contracts support CBLB502 for defense and limited medical applications:
– Continually seeking new grants and contracts as well as modifications to existing grants and contracts to maximize availability of non-dilutive financing
• Pro forma cash at September 30, 2011: $34 million
– Recognizes $9 million investment made by Rusnano in majority owned subsidiary Panacela Labs, Inc. on October 4, 2011
• Other: – $5 million Russian government Skolkovo grant to Incuron, LLC subsidiary – $7 million milestone investment into Incuron, LLC subsidiary, pending
opening of Russian IND for clinical study of CBLC137
Yakov Kogan, PhD, MBA
Interim Chief Executive Officer
• SVP of Basic Science, Roswell Park Cancer Institute
• Former Chair, Dept. Molecular Biology at Cleveland Clinic
• 30+ issued patents
• 150+ research publications
Andrei Gudkov, PhD, D.Sci
Chief Scientific Officer
• 30 years of financial and operations management and accounting experience
• 6 years as CFO of a public biotech company
• 15 years experience in federal contracting
Michael Fonstein, PhD
President
Neil Lyons, CPA
Chief Financial Officer
Senior Management Team
• 25 years global oncology drug development experience
• Senior positions in clinical operations at CROs
• Led clinical development in several publicly traded biotech companies
Michael Kurman, MD
Chief Medical Officer
• Over 20 years of regulatory experience at large and small pharma
• Multiple successful NDAs, MAAs, sNDAs, advisory committees
Ann Hards, PhD
Executive Vice President, Regulatory Affairs and Quality Assurance
36
• Former Director of Business Development at Integrated Genomics, Inc.
• Expert in technical sales and contract negotiations
• Scientist and entrepreneur
• Founder of The Fellowship for Interpretation of Genomes (FIG)
• Founder and Former CEO of Integrated Genomics, Inc. (‘97-03)
Scientific Advisory Board
George R. Stark, PhD Chairman of SAB, Member of NAS, Former Director of Lerner Research Institute of Cleveland Clinic, Scientific Advisor to Amersham and Genentech, pioneered numerous major research technologies
Inder Verma, PhD Member of NAS, Professor of Salk Institute, Founder and Scientific Advisor to Cell Genesys, Signal Pharmaceuticals, UroGenesys, Ventana Pharmaceuticals, Quark Biotech. Internationally recognized leader in cancer biology and inflammation
Bruce Blazar, MD Professor, Chair in Transplantation Immunology of University of Minnesota. Member of the FDA Advisory Committee, SAB member of BioMarin Pharmaceutical, Seattle Genetics, etc.
Board of Directors
Independent Directors
Bernard L. Kasten, MD Former CEO, SIGA Technologies David Hohn, MD Former President of Roswell Park Cancer
Institute James Antal, CPA, MBA Former CFO and CIO of Experian
Paul DiCorleto, PhD Chairman Lerner Research Institute,
Cleveland Clinic
Management
Yakov Kogan, PhD, MBA Interim CEO, Cleveland BioLabs, Inc. Michael Fonstein, PhD President, Cleveland BioLabs, Inc. Andrei Gudkov, PhD, DSci CSO, Cleveland BioLabs, Inc.
Boards
37
Bibliography
1. Burdelya, et al. (2008) An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320(5873): p. 226-230
2. Burdelya, et al. (2011) Toll-like Receptor 5 Agonist Protects Mice from Dermatitis and Oral Mucositis Caused by Local Radiation: Implications for Head-and-Neck Cancer Radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., Oct.14 (e-pub ahead of print)
3. Fukuzawa et al. (2011) A TLR5 agonist inhibits acute renal ischemic failure. J Immunol. 187: 3831-9
4. Yoon et al. (2012) Structural basis of TLR5-flagellin recognition and signaling. Science (in press)
5. Singh et al. (2011) CBLB613: A TLR 2/6 Agonist, Natural Lipopeptide of Mycoplasma arginini , as a Novel Radiation Countermeasure. Radiat Res. Dec 16
6. Gasparian et al. (2011) Curaxins: Anticancer Compounds that Simultaneously Suppress NH-kB and Activate p53 by Targeting FACT. Science Transl Med 3(95):95ra72
7. Gasparian et al. (2010) Inhibition of encephalomyocarditis virus and poliovirus replication by quinacrine: implications for the design and discovery of novel antiviral drugs. J.Virol. 84 (18): 9390-7
8. Neznanov et al. (2009) Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle 8(23):3960-70
9. Guo C. et al. (2009) 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. Oncogene 28(8): 1151-61
10. Draetta GF, Depinho RA. (2011) Cancer drug discovery faces the FACT. Science Transl Med. 3(95):95ps34
38
Top Related